Scan to find a protein on pancreatic and stomach cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a special PET scan to see if a new imaging agent can find a protein called claudin 18.2 on cancer cells in pancreatic, stomach, or gastroesophageal junction cancers. The scan may help doctors better see the cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with pancreatic cancer or cancer of the stomach or the area where the stomach meets the esophagus.
- Your cancer must show any level of a protein called claudin 18.2 (usually found by a biopsy test).
- You can be newly diagnosed and eligible for surgery, or have cancer that came back after surgery, or have cancer that became removable after other treatments.
- You must be between 18 and 75 years old.
- You must be generally healthy, with a life expectancy of more than 6 months.
- You cannot have had prior treatment that specifically targets claudin 18.2, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radioactive drug that targets a protein called Claudin 18.2 found on some stomach and pancreatic cancer cells. Researchers will track where the drug goes in your body and how it exits, to see if it's a safe and effective way to deliver radiation directly to tumors.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This study uses a special PET scan to look for a protein called CLDN18.2 on cancer cells. It may help doctors better understand certain cancers like stomach, pancreas, bile duct, or esophageal cancer and guide treatment decisions.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.